☆ 4.8 Article

Risk factors and outcome of Chimeric Antigen Receptor T-Cell patients admitted to Pediatric Intensive Care Unit: CART-PICU study

FRONTIERS IN IMMUNOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Hematology

Preinfusion factors impacting relapse immunophenotype following CD19 CART cells

Adam J. Lamble et al.

Summary: Relapse following CAR T-cell therapy for r/r B-ALL presents different patterns, including CD19pos relapse, CD19neg relapse, and LS relapse. Various preinfusion risk factors are associated with different relapse patterns, including a greater number of prior complete remissions for CD19pos relapse, high preinfusion disease burden, prior blinatumomab nonresponse, older age, and 4-1BB CAR construct for CD19neg relapse, and the presence of KMT2A rearrangement for LS relapse. The overall survival following post-CAR relapse is poor, particularly for LS relapse. It is crucial to study relapse prevention strategies, such as hematopoietic stem cell transplantation, in prospective clinical trials.

BLOOD ADVANCES (2023)

Add to Collection

Article Hematology

Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia

Alan S. Wayne et al.

Summary: This study evaluated the safety and efficacy of KTEX19, an autologous anti-CD19 CAR T-cell therapy, in pediatric/adolescent patients with relapsed/refractory B-cell acute lymphoblastic leukemia. After a single dose of KTE-X19, high complete remission rates with manageable safety profile were achieved in these patients.

HAEMATOLOGICA (2023)

Add to Collection

Article Hematology

Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome

Melissa R. Hines et al.

TRANSPLANTATION AND CELLULAR THERAPY (2023)

Add to Collection

Article Pediatrics

Outcomes for paediatric acute leukaemia patients admitted to the paediatric intensive care unit

Marina Caballero et al.

Summary: In this study, it was found that the main cause of admission for children with acute leukaemia was infection, which was associated with more severity and longer hospital stay. The use of inotropic support and mechanical ventilation was also common in treating these patients.

EUROPEAN JOURNAL OF PEDIATRICS (2022)

Add to Collection

Article Oncology

Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL

Regina M. Myers et al.

Summary: This retrospective study investigates the impact of CD19-CAR therapy on relapsed or refractory ALL patients, revealing that nonresponse to blinatumomab and high disease burden are associated with worse survival outcomes.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) following treatment with tisagenlecleucel

Reyes Maria Martin-Rojas et al.

Summary: Chimeric antigen receptor (CAR) T cell-related HLH/MAS is an unusual manifestation of severe cytokine release syndrome (CRS) with a poor prognosis and difficult diagnosis. Establishing specific diagnostic criteria is essential, and incorporating multiple CAR T-cell follow-up techniques allows for more precise management of this complication.

CLINICAL CASE REPORTS (2022)

Add to Collection

Article Oncology

Infectious Complications in Pediatric, Adolescent and Young Adult Patients Undergoing CD19-CAR T Cell Therapy

Gabriela M. Maron et al.

Summary: CD19-specific CAR T cell therapy has revolutionized the treatment of relapsed/refractory B-ALL in pediatric and AYA patients. However, the infectious disease challenges associated with this therapy are not well understood. This study examines the infections that occurred in pediatric and AYA patients after receiving CD19-CAR T cells and identifies risk factors for infection. The results show that infections are common in the first 90 days after CAR T cell therapy, with bacterial infections being more frequent early on and viral infections occurring throughout the post-infusion period. The study highlights the need for further research to improve surveillance, prophylaxis, and treatment strategies for infectious complications.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Letter Hematology

Anakinra utilization in refractory pediatric CAR T-cell associated toxicities

Caroline Diorio et al.

BLOOD ADVANCES (2022)

Add to Collection

Article Hematology

Dramatic Recovery after Etoposide Phosphate Infusion for Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome following Treatment with Tisagenlecleucel in a Young Patient with Relapsed Acute Lymphoblastic Leukemia: A Case Report

Pierre Peterlin et al.

Summary: The occurrence of HLH/MAS after CAR T-cell infusion is rare and fatal. This report highlights the successful treatment of HLH/MAS following CAR T-cell infusion using etoposide phosphate, emphasizing the importance of monitoring and the potential benefits of EP treatment.

ACTA HAEMATOLOGICA (2022)

Add to Collection

Article Critical Care Medicine

Outcomes of Critically Ill Children With Acute Lymphoblastic Leukemia and Cytokine Release Syndrome Due to Chimeric Antigen Receptor T Cell Therapy: US, Multicenter PICU, Cohort Database Study

Grace E. Logan et al.

Summary: This study aimed to characterize the critical illness outcomes in pediatric acute lymphoblastic leukemia (ALL) patients with cytokine release syndrome (CRS). The results showed that most patients received high levels of support in the pediatric intensive care unit (PICU) and the majority survived their hospitalization.

PEDIATRIC CRITICAL CARE MEDICINE (2022)

Add to Collection

Article Oncology

A multicenter study of ICU resource utilization in pediatric, adolescent and young adult patients post CAR-T therapy

Dristhi Ragoonanan et al.

Summary: Tisagenlecleucel has shown remarkable outcomes in treating refractory B-cell acute lymphoblastic leukemia (ALL) patients up to the age of 25. However, access to this treatment is limited to higher-resource and certified centers due to unique and potentially life-threatening complications. This multicenter study compared the outcomes of ALL patients receiving Tisagenlecleucel with those receiving conventional chemotherapy, with a focus on pediatric intensive care support.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Review Hematology

Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review

Shakira J. Grant et al.

Summary: CAR-T cell therapy is a novel treatment for patients with relapsed or refractory hematologic malignancies, often leading to symptoms of ICANS. Studies have found that the clinical presentation, onset, severity, and acute or long-term outcomes of ICANS vary.

TRANSPLANTATION AND CELLULAR THERAPY (2022)

Add to Collection

Review Oncology

Side-effect management of chimeric antigen receptor (CAR) T-cell therapy

M-L Schubert et al.

Summary: CAR T-cell therapy targeting CD19-expressing B cells has shown promising results in treating refractory and/or relapsed B-cell malignancies, but also presents challenges such as cytokine release syndrome and neurotoxicity syndrome. Optimal management strategies for the side-effects associated with CAR T-cell therapy are crucial as it expands into other diseases in hematology and oncology.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Biotechnology & Applied Microbiology

CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+Relapsed/Refractory Malignancies

Valentin Ortiz-Maldonado et al.

Summary: Evaluation of ARI-0001 cell administration in patients with relapsed/refractory CD19(+) malignancies showed significant efficacy in ALL patients, with low rates of neurotoxicity and procedure-related mortality.

MOLECULAR THERAPY (2021)

Add to Collection

Article Oncology

Factors associated with the clinical outcome of patients with relapsed/refractory CD19+ acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy

Valentin Ortiz-Maldonado et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Article Oncology

Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia

Marie-Emilie Dourthe et al.

Summary: Tisagenlecleucel therapy has shown promising efficacy in relapsed/refractory BCP-ALL patients, with a high complete remission rate at D28. However, factors such as prior therapy and disease burden can impact the risk of relapse and overall survival. Detectable MRD at D28 and loss of BCA may define patients at high risk of relapse, requiring additional interventions.

LEUKEMIA (2021)

Add to Collection

Article Hematology

Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study

Élie Azoulay et al.

Lancet Haematology (2021)

Add to Collection

Article Hematology

Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy

Melissa R. Hines et al.

Summary: CAR T-cell therapy can lead to severe toxicity resembling carHLH, occurring in 14.8% of pediatric and young adult patients. Diagnosis and treatment of carHLH require suspicion and immunomodulation therapy, showing variable responses. Patients with carHLH have reduced response to therapy and overall survival compared to those without carHLH.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Review Oncology

A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains

Kathryn M. Cappell et al.

Summary: CAR T cell therapies targeting haematological malignancies show promising efficacy, with CD28- and 4-1BB-derived costimulatory domains demonstrating potentially different cellular and clinical effects. Further research is needed to compare their effectiveness and toxicity profiles.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

Add to Collection

Article Hematology

Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

Ibrahim Yakoub-Agha et al.

HAEMATOLOGICA (2020)

Add to Collection

Article

Inpatient and Intensive Care Unit Resource Utilization after CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy (CART19) for Pediatric Acute Lymphoblastic Leukemia (ALL)

Regina M. Myers et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)

Add to Collection

Article Hematology

Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma

Marcelo C. Pasquini et al.

BLOOD ADVANCES (2020)

Add to Collection

Article Hematology

Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management

Martina Pennisi et al.

BLOOD ADVANCES (2020)

Add to Collection

Article Oncology

Managing the toxicities of CAR T-cell therapy

Sattva S. Neelapu

HEMATOLOGICAL ONCOLOGY (2019)

Add to Collection

Article Oncology

Predictors of mortality after admission to pediatric intensive care unit in oncohematologic patients without history of hematopoietic stem cell transplantation: A single-center experience

Marta Pillon et al.

PEDIATRIC BLOOD & CANCER (2019)

Add to Collection

Article Hematology

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

Daniel W. Lee et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)

Add to Collection

Review Hematology

Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management

Jennifer N. Brudno et al.

BLOOD REVIEWS (2019)

Add to Collection

Review Oncology

Chimeric antigen receptor T-cell therapy - assessment and management of toxicities

Sattva S. Neelapu et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2018)

Add to Collection

Review Oncology

Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel

David Porter et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)

Add to Collection

Review Oncology

Cytokine release syndrome

Alexander Shimabukuro-Vornhagen et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)

Add to Collection

Article Clinical Neurology

Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema

Matthew Torre et al.

JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2018)

Add to Collection

Article Critical Care Medicine

Validation of the Vasoactive-Inotropic Score in Pediatric Sepsis

Amanda M. McIntosh et al.

PEDIATRIC CRITICAL CARE MEDICINE (2017)

Add to Collection

Article Hematology

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

Rebecca A. Gardner et al.

BLOOD (2017)

Add to Collection

Article Critical Care Medicine

Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia

Julie C. Fitzgerald et al.

CRITICAL CARE MEDICINE (2017)

Add to Collection

Review Hematology

Current concepts in the diagnosis and management of cytokine release syndrome

Daniel W. Lee et al.

BLOOD (2014)

Add to Collection

Article Medicine, General & Internal

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Shannon L. Maude et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection

Article Cell Biology

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

Marco L. Davila et al.

SCIENCE TRANSLATIONAL MEDICINE (2014)

Add to Collection

© Peeref 2019-2024. All rights reserved.